Schmidlap,
I very much enjoyed reading your post. I have said it before and I'll say it again. It's one thing for us to read stuff in text books, to read articles on the Web, but it is quite another to get actual views and thoughts from people that have experienced it for themselves and have done the research for themselves, you automatically have a vested interest and the depth of your own research increases proportionately when it becomes personalised.
It was a good insight to read your findings and how you weighed each point up. In the same way patients will vote with their feet once they know there is a real alternative to the current std of care and treatments such as stem cells. I'm in no way discounting stem cell therapies altogether. In fact there may possibly be instances where iPPS might not work in some rare cases and it could be SC to the rescue? I do feel that we will be numero uno for the vast vast majority of OA sufferers though and after you too have weighed up several options you also have come to the same conclusion. We really will be able to cater for the mass market and it won't be prohibitively expensive either.
I'm certainly no Doc but I have heard of a number of cases where patients have thought surgery was inevitable but iPPS has given them a real and viable chance of not needing it...ever. No idea what percentage this is, how many cases, what the criteria is...I'm just putting it out there. If you need more evidence of my findings, ask Paul himself. His Doc assessed him more than 8 years ago and insisted that he too would need surgery (Total Knee Replacement) one day and probably within a couple of years (ie 6 years ago)....Paul started on iPPS 8 years ago...he hasn't had surgery yet.
DYOR
- Forums
- ASX - By Stock
- PAR
- PAR, the Moat and a Recipe for success
PAR
paradigm biopharmaceuticals limited..
Add to My Watchlist
4.76%
!
44.0¢

PAR, the Moat and a Recipe for success, page-8
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
44.0¢ |
Change
0.020(4.76%) |
Mkt cap ! $174.8M |
Open | High | Low | Value | Volume |
42.5¢ | 46.0¢ | 42.0¢ | $347.2K | 796.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 16968 | 44.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
45.5¢ | 2449 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 16968 | 0.440 |
1 | 10000 | 0.435 |
3 | 17957 | 0.430 |
2 | 82297 | 0.420 |
3 | 40881 | 0.415 |
Price($) | Vol. | No. |
---|---|---|
0.455 | 2449 | 1 |
0.460 | 29978 | 2 |
0.465 | 112360 | 2 |
0.470 | 87163 | 5 |
0.475 | 46456 | 2 |
Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online